Li Watsek
Stock Analyst at Cantor Fitzgerald
(0)
# 4565
Out of 5,218 analysts
81
Total ratings
32.43%
Success rate
-14.43%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Kura Oncology | Reiterates: Overweight | n/a | n/a | n/a | 10 | Dec 9, 2024 | |
Affimed | Reiterates: Overweight | n/a | n/a | n/a | 7 | Nov 19, 2024 | |
Ascendis Pharma | Reiterates: Overweight | 170 170 | 130.25 | 30.52% | 15 | Nov 15, 2024 | |
ALX Oncology Holding... | Reiterates: Overweight | n/a | n/a | n/a | 5 | Nov 12, 2024 | |
Arcus Biosciences | Reiterates: Overweight | n/a | n/a | n/a | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 4 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 20 20 | 9.37 | 113.45% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 3 | 0.88 | 240.91% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 220 | 3.12 | 6951.28% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 26 | n/a | n/a | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 5 | 1.82 | 174.73% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 38 | 0.19 | 19900% | 2 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 38 | 2.35 | 1517.02% | 1 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 75 69 | n/a | n/a | 2 | Aug 9, 2022 |